Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance

Antzeko izenburuak

• Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
  nork: Giugliano, Robert P., et al.
  Argitaratua: (2021)
• Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
  nork: Raschi, Emanuel, et al.
  Argitaratua: (2020)
• Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
  nork: Gatti, Milo, et al.
  Argitaratua: (2020)
• Recurrence of pericarditis after influenza vaccination: a case report and review of the literature
  nork: Mei, Riccardo, et al.
  Argitaratua: (2018)
• Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
  nork: Raschi, Emanuel, et al.
  Argitaratua: (2021)